BrainDTech
BrainDTech – Early Detection of Brain Diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| N/A | €202k | Series B | |
| Total Funding | 000k | ||
| EUR | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 443 % | (8 %) | (5 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (190 %) | 7 % | 18 % | 19 % |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (59 %) | 4 % | 1 % | (1 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
BrainDTech specializes in the early detection and monitoring of neurological and neurodegenerative diseases through liquid biopsies, focusing on miRNA from microglial microvesicles. Operating in the biotechnology sector, BrainDTech serves healthcare providers, research institutions, and pharmaceutical companies. The company has developed a patented method for diagnosing, prognosing, and monitoring treatment of neurodegenerative, neurological, and inflammatory diseases. This method leverages the unique miRNA signatures found in microvesicles released by inflamed microglia, which can be collected from liquid biopsies. By identifying these miRNA patterns, BrainDTech provides an unprecedented level of understanding of brain disease scenarios, enabling early and precise diagnostics crucial for effective treatment. The business model is primarily B2B, generating revenue through partnerships, licensing agreements, and sales of diagnostic kits and services.
Keywords: miRNA, microglial microvesicles, liquid biopsies, neurodegenerative diseases, early detection, diagnostics, biotechnology, precision medicine, patented method, healthcare.